Please assess the completion status of the following clinical trial:

Trial Title: Variable Ventilation During Acute Respiratory Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: DEVICE_FEASIBILITY
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria~1. Age \> or equal to 18~2. Requires mechanical ventilation using a volume-controlled mode.~3. Admitted to Boston Medical Center Surgical, Medical, or Coronary Intensive Care Unit~4. Evidence of impaired oxygenation on mechanical ventilator defined by PaO2/FiO2 ratio less than 350 (corresponding to an A-a gradient of approximately 100) or SatO2/FiO2 ratio less than 358 (requiring O2 saturation less than or equal to 97%).~5. Meets Clinical Stability Criteria (on maximum of one vasopressor medication) for at least one hour prior to start of study protocol:~5a. Hemodynamically stable: mean arterial pressure greater than 60 mmHg, heart rate greater than 50 and less than 130 bpm 5b. Respiratory system stable: Respiratory rate less than 35 bpm, O2 saturation greater than 88%, peak pressure on ventilator less than 40 cm H20, FiO2 not greater than 0.80, PEEP level not greater than 12.5 cm H2O, requires suctioning less than once hourly.~5c. Acid-base stability: pH greater than 7.2 and less than 7.55 5d. Neurologic system stable: No agitation as defined by a Riker SAS Score between 2 (very sedated) and 4 (calm and cooperative) 6. Assent of primary ICU care team~Exclusion Criteria~1. Do not resuscitate order~2. Increased intracranial pressure~3. Pregnancy (urine pregnancy test for all women of child-bearing age)~4. Planned transport out of ICU during planned study protocol~5. Coagulopathy (INR \> 2.0 or PTT \> 50)~6. Severe thrombocytopenia (platelets \< 20,000)~7. Patients receiving medications meant to increase oxygenation such as inhaled nitric oxide, inhaled prostacyclin, intravenous prostacyclin, and intravenous treprostinil~8. Any patient receiving a medication that is not consistent with FDA-approved labeling~9. A change in the Riker SAS during the study protocol that results in a Riker SAS score of 1: Unarousable (minimal or no response to noxious stimuli, does not communicate or follow commands) or 5: Agitation (anxious or physically agitated, calms to verbal instructions) for a duration of greater than 15 minutes~10. A Riker SAS of 6: Very agitated (requiring restraint and frequent verbal reminding of limits, biting ETT) or higher will result in immediate study discontinuation for the individual participant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- variable ventilation (Type: EXPERIMENTAL): A novel means of conducting mechanical ventilation that involves an approximately 40% variation in tidal volume around a set mean tidal volume
- conventional ventilation (Type: OTHER): This is the control arm of the study, in which tidal volume will be set as the patient's baseline tidal volume prior to study entry and will not vary.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues